Literature DB >> 18192684

Pre- and post-exposure prophylaxis of experimental Burkholderia pseudomallei infection with doxycycline, amoxicillin/clavulanic acid and co-trimoxazole.

Suppiah Paramalingam Sivalingam1, Siew Hoon Sim, Liaw Chin Wen Jasper, Dongling Wang, Yichun Liu, Eng Eong Ooi.   

Abstract

OBJECTIVES: Melioidosis, a potentially fatal disease of humans and animals, is caused by the gram-negative bacterium, Burkholderia pseudomallei. There is no approved vaccine or effective prophylaxis. Given its potential as a bioterrorism agent and a cause of serious laboratory-acquired infection, we studied the efficacy of pre- and post-exposure oral antibiotic prophylaxis in BALB/c mice infected with aerosolized B. pseudomallei through the inhalational route.
METHODS: Amoxicillin/clavulanic acid, doxycycline or co-trimoxazole was administered 48 h before infection as pre-exposure prophylaxis, orally, twice daily and continued up to 10 days post-challenge. In the post-exposure prophylaxis regimen, the oral antibiotics were administered twice daily, at 0, 10, 24 and 48 h and continued for 10 days. Survival of all animals was observed until 21 days.
RESULTS: All infected control animals developed infection between 24 and 48 h, and died within 5 days. Animals receiving amoxicillin/clavulanic acid as pre-exposure prophylaxis succumbed to the disease at day 7, whereas those in the co-trimoxazole and doxycycline groups had survival rate of 100% and 80%, respectively, at day 21. As post-exposure prophylaxis, all antibiotics were not effective when treatment was initiated 48 h post-challenge. However, animals receiving co-trimoxazole had a 100% survival rate when the antibiotic was started 0, 10 and 24 h post-infection, and amoxicillin/clavulanic acid was the least effective.
CONCLUSIONS: Co-trimoxazole appears to be an effective oral antibiotic both as pre- and post-exposure prophylaxis to B. pseudomallei. Data derived from this study have important implications on the management of laboratory accidents or following an intentional release of B. pseudomallei, a potential bioterrorism agent.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18192684     DOI: 10.1093/jac/dkm527

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  21 in total

Review 1.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  In-Vitro Activity of Doxycycline and β-Lactam Combinations Against Different Strains of Burkholderia pseudomallei.

Authors:  Nurul Iman Mohamad; Azian Harun; Habsah Hasan; Zakuan Zainy Deris
Journal:  Indian J Microbiol       Date:  2018-03-26       Impact factor: 2.461

Review 3.  Human Melioidosis.

Authors:  I Gassiep; M Armstrong; R Norton
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

4.  Metaphylactic Antibiotic Treatment to Prevent the Transmission of Corynebacterium bovis to Immunocompromised Mouse Offspring.

Authors:  Emily C Pearson; Umarani Pugazhenthi; Derek L Fong; Derek E Smith; Andrew G Nicklawsky; Lauren M Habenicht; Michael K Fink; Jori K Leszczynski; Michael J Schurr; Christopher A Manuel
Journal:  J Am Assoc Lab Anim Sci       Date:  2020-09-09       Impact factor: 1.232

5.  In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam-Durlobactam against Pathogenic Burkholderia Species.

Authors:  Krisztina M Papp-Wallace; Adam B Shapiro; Scott A Becka; Elise T Zeiser; John J LiPuma; Douglas J Lane; Rekha G Panchal; John P Mueller; John P O'Donnell; Alita A Miller
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

6.  Present and future therapeutic strategies for melioidosis and glanders.

Authors:  D Mark Estes; Steven W Dow; Herbert P Schweizer; Alfredo G Torres
Journal:  Expert Rev Anti Infect Ther       Date:  2010-03       Impact factor: 5.091

7.  Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei.

Authors:  Sharon J Peacock; Herbert P Schweizer; David A B Dance; Theresa L Smith; Jay E Gee; Vanaporn Wuthiekanun; David DeShazer; Ivo Steinmetz; Patrick Tan; Bart J Currie
Journal:  Emerg Infect Dis       Date:  2008-07       Impact factor: 6.883

Review 8.  Burkholderia pseudomallei: Challenges for the Clinical Microbiology Laboratory.

Authors:  Peera Hemarajata; Jonathan D Baghdadi; Risa Hoffman; Romney M Humphries
Journal:  J Clin Microbiol       Date:  2016-09-21       Impact factor: 5.948

9.  Comparison of the in vitro and in vivo susceptibilities of Burkholderia mallei to Ceftazidime and Levofloxacin.

Authors:  Barbara M Judy; Gregory C Whitlock; Alfredo G Torres; D Mark Estes
Journal:  BMC Microbiol       Date:  2009-05-09       Impact factor: 3.605

10.  Recovery efficiencies for Burkholderia thailandensis from various aerosol sampling media.

Authors:  Paul Dabisch; Kristin Bower; Brandi Dorsey; Loni Wronka
Journal:  Front Cell Infect Microbiol       Date:  2012-06-11       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.